EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2022 update on diagnosis, risk-stratification, and management.
Journal
American journal of hematology
ISSN: 1096-8652
Titre abrégé: Am J Hematol
Pays: United States
ID NLM: 7610369
Informations de publication
Date de publication:
07 2022
07 2022
Historique:
revised:
12
04
2022
received:
02
03
2022
accepted:
16
04
2022
pubmed:
27
4
2022
medline:
16
6
2022
entrez:
26
4
2022
Statut:
ppublish
Résumé
Epstein Barr virus-positive (EBV+) diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) is an entity included in the WHO classification of lymphoid neoplasms since 2016. EBV+ DLBCL, NOS, is an aggressive B-cell lymphoma associated with EBV infection, and a poor prognosis with standard chemotherapeutic approaches. The diagnosis is made through a careful pathological evaluation. Detection of EBV-encoded RNA (EBER) is considered standard for diagnosis; however, a clear cutoff for percentage of positive cells has not been defined. The differential diagnosis includes plasmablastic lymphoma (PBL), DLBCL associated with chronic inflammation, primary effusion lymphoma (PEL), among others. The International Prognostic Index (IPI) and the Oyama score can be used for risk-stratification. The Oyama score includes age >70 years and presence of B symptoms. The expression of CD30 and PD-1/PD-L1 are emerging as potential adverse but targetable biomarkers. Patients with EBV+ DLBCL, NOS, should be staged and managed following similar guidelines than patients with EBV-negative DLBCL. EBV+ DLBCL, NOS, however, might have a worse prognosis than EBV-negative DLBCL in the era of chemoimmunotherapy. Therefore, the inclusion of patients in clinical trials when available is recommended. There is an opportunity to study and develop targeted therapy in the management of patients with EBV+ DLBCL, NOS.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
951-965Informations de copyright
© 2022 Wiley Periodicals LLC.
Références
Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375-2390. doi:10.1182/BLOOD-2016-01-643569
Oyama T, Ichimura K, Suzuki R, et al. Senile EBV+ B-cell lymphoproliferative disorders: a clinicopathologic study of 22 patients. Am J Surg Pathol. 2003;27(1):16-26. doi:10.1097/00000478-200301000-00003
Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011;117(19):5019-5032. doi:10.1182/BLOOD-2011-01-293050
Smatti MK, Al-Sadeq DW, Ali NH, Pintus G, Abou-Saleh H, Nasrallah GK. Epstein-Barr virus epidemiology, serology, and genetic variability of LMP-1 oncogene among healthy population: an update. Front Oncol. 2018;8(JUN):211. doi:10.3389/FONC.2018.00211
Park S, Lee J, Young HK, et al. The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma. Blood. 2007;110(3):972-978. doi:10.1182/BLOOD-2007-01-067769
Hofscheier A, Ponciano A, Bonzheim I, et al. Geographic variation in the prevalence of Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly: a comparative analysis of a Mexican and a German population. Mod Pathol. 2011;24(8):1046-1054. doi:10.1038/MODPATHOL.2011.62
Hoeller S, Tzankov A, Pileri SA, Went P, Dirnhofer S. Epstein-Barr virus-positive diffuse large B-cell lymphoma in elderly patients is rare in Western populations. Hum Pathol. 2010;41(3):352-357. doi:10.1016/J.HUMPATH.2009.07.024
Beltran BE, Castillo JJ, Morales D, et al. EBV-positive diffuse large B-cell lymphoma of the elderly: a case series from Peru. Am J Hematol. 2011;86(8):663-667. doi:10.1002/AJH.22078
Ok CY, Li L, Xu-Monette ZY, et al. Prevalence and clinical implications of epstein-barr virus infection in de novo diffuse large B-cell lymphoma in Western countries. Clin Cancer Res. 2014;20(9):2338-2349. doi:10.1158/1078-0432.CCR-13-3157
Montes-Moreno S, Odqvist L, Diaz-Perez JA, et al. EBV-positive diffuse large B-cell lymphoma of the elderly is an aggressive post-germinal center B-cell neoplasm characterized by prominent nuclear factor-kB activation. Mod Pathol. 2012;25(7):968-982. doi:10.1038/MODPATHOL.2012.52
Green MR, Rodig S, Juszczynski P, et al. Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy. Clin Cancer Res. 2012;18(6):1611-1618. doi:10.1158/1078-0432.CCR-11-1942
Bi XW, Wang H, Zhang WW, et al. PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma. J Hematol Oncol. 2016;9(1):109. doi:10.1186/S13045-016-0341-7
Cohen M, Vistarop AG, Huaman F, et al. Cytotoxic response against Epstein Barr virus coexists with diffuse large B-cell lymphoma tolerogenic microenvironment: clinical features and survival impact. Sci Rep. 2017;7(1). doi:10.1038/S41598-017-11052-Z
Dolcetti R. Cross-talk between Epstein-Barr virus and microenvironment in the pathogenesis of lymphomas. Semin Cancer Biol. 2015;34:58-69. doi:10.1016/J.SEMCANCER.2015.04.006
Nicolae A, Pittaluga S, Abdullah S, et al. EBV-positive large B-cell lymphomas in young patients: a nodal lymphoma with evidence for a tolerogenic immune environment. Blood. 2015;126(7):863-872. doi:10.1182/BLOOD-2015-02-630632
Zhou Y, Xu Z, Lin W, et al. Comprehensive genomic profiling of EBV-positive diffuse large B-cell lymphoma and the expression and Clinicopathological correlations of some related genes. Front Oncol. 2019;9:683. doi:10.3389/FONC.2019.00683
Ok CY, Ye Q, Li L, et al. Age cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphoma-is it necessary? Oncotarget. 2015;6(16):13933-13945. doi:10.18632/ONCOTARGET.4324
Lu TX, Liang JH, Miao Y, et al. Epstein-Barr virus positive diffuse large B-cell lymphoma predict poor outcome, regardless of the age. Sci Rep. 2015;5:12618. doi:10.1038/SREP12168
Beltran BE, Morales D, Quiñones P, Medeiros LJ, Miranda RN, Castillo JJ. EBV-positive diffuse large b-cell lymphoma in young immunocompetent individuals. Clin Lymphoma Myeloma Leuk. 2011;11(6):512-516. doi:10.1016/J.CLML.2011.07.003
Tokuyama K, Okada F, Sato H, et al. Computed tomography findings in Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphoma (DLBCL) of the elderly: comparison with EBV-negative DLBCL. Br J Radiol. 2017;90(1072):20160879. doi:10.1259/BJR.20160879
Liang JH, Lu TX, Tian T, et al. Epstein-Barr virus (EBV) DNA in whole blood as a superior prognostic and monitoring factor than EBV-encoded small RNA in situ hybridization in diffuse large B-cell lymphoma. Clin Microbiol Infect. 2015;21(6):596-602. doi:10.1016/J.CMI.2015.02.017
Ok CY, Papathomas TG, Medeiros LJ, Young KH. EBV-positive diffuse large B-cell lymphoma of the elderly. Blood. 2013;122(3):328-340. doi:10.1182/BLOOD-2013-03-489708
Shen Z, Hu L, Yao M, et al. Disparity analysis and prognostic value of pretreatment whole blood Epstein-Barr virus DNA load and Epstein-Barr encoding region status in lymphomas: a retrospective multicenter study in Huaihai lymphoma working group. Int J Cancer. 2022;150(2):327-334. doi:10.1002/IJC.33802
Ohashi A, Kato S, Okamoto A, et al. Reappraisal of Epstein-Barr virus (EBV) in diffuse large B-cell lymphoma (DLBCL): comparative analysis between EBV-positive and EBV-negative DLBCL with EBV-positive bystander cells. Histopathology. 2017;71(1):89-97. doi:10.1111/HIS.13197
Bourbon E, Maucort-Boulch D, Fontaine J, et al. Clinicopathological features and survival in EBV-positive diffuse large B-cell lymphoma not otherwise specified. Blood Adv. 2021;5(16):3227-3239. doi:10.1182/BLOODADVANCES.2021004515
Gao X, Li J, Wang Y, Liu S, Yue B. Clinical characteristics and prognostic significance of EBER positivity in diffuse large B-cell lymphoma: a meta-analysis. PLoS ONE. 2018;13(6):e0199398. doi:10.1371/JOURNAL.PONE.0199398
Hwang J, Suh CH, Kim KW, et al. The incidence of Epstein-Barr virus-positive diffuse large B-cell lymphoma: a systematic review and meta-analysis. Cancers (Basel). 2021;13(8):1785. doi:10.3390/CANCERS13081785
Takahara T, Satou A, Ishikawa E, et al. Clinicopathological analysis of neoplastic PD-L1-positive EBV + diffuse large B cell lymphoma, not otherwise specified, in a Japanese cohort. Virchows Arch. 2021;478(3):541-552. doi:10.1007/S00428-020-02901-W
Kimura S, Oshiro Y, Iwasaki H, et al. Programmed cell death-ligand 1 (PD-L1) + tumour cells and low-reacting programmed cell death 1 (PD1) + tumour-infiltrating lymphocytes predict poor prognosis in Epstein-Barr virus + diffuse large B-cell lymphoma. Clin Exp Med. Published online September 13, 2021. doi:10.1007/S10238-021-00754-4
Liu F, Wang Z, Zhou X, et al. Genetic heterogeneity and mutational signature in Chinese Epstein-Barr virus-positive diffuse large B-cell lymphoma. PLoS ONE. 2018;13(8):e0201456. doi:10.1371/JOURNAL.PONE.0201546.
Chabay P. Advances in the pathogenesis of EBV-associated diffuse large B cell lymphoma. Cancers (Basel). 2021;13(11):2717. doi:10.3390/CANCERS13112717
Kimura H, Okuno Y, Sato Y, Watanabe T, Murata T. Deletion of viral microRNAs in the Oncogenesis of Epstein-Barr virus-associated lymphoma. Front Microbiol. 2021;12:667968. doi:10.3389/FMICB.2021.667968
Chapman JR, Bouska AC, Zhang W, et al. EBV-positive HIV-associated diffuse large B cell lymphomas are characterized by JAK/STAT (STAT3) pathway mutations and unique clinicopathologic features. Br J Haematol. 2021;194(5):870-878. doi:10.1111/BJH.17708
Leeman-Neill RJ, Soderquist CR, Montanari F, et al. Phenogenomic heterogeneity of post-transplant plasmablastic lymphomas. Haematologica. 2022;107(1):201-210. doi:10.3324/HAEMATOL.2020.267294
Castillo JJ, Bibas M, Miranda RN. The biology and treatment of plasmablastic lymphoma. Blood. 2015;125(15):2323-2330. doi:10.1182/BLOOD-2014-10-567479
Marques-Piubelli ML, Salas YI, Pachas C, Becker-Hecker R, Vega F, Miranda RN. Epstein-Barr virus-associated B-cell lymphoproliferative disorders and lymphomas: a review. Pathology. 2020;52(1):40-52. doi:10.1016/J.PATHOL.2019.09.006
Lopez A, Abrisqueta P. Plasmablastic lymphoma: current perspectives. Blood Lymphat Cancer. 2018;8:63-70. doi:10.2147/BLCTT.S142814
Mori H, Fukatsu M, Ohkawara H, et al. Heterogeneity in the diagnosis of plasmablastic lymphoma, plasmablastic myeloma, and plasmablastic neoplasm: a scoping review. Int J Hematol. 2021;114(6):639-652. doi:10.1007/S12185-021-03211-W
Ramis-Zaldivar JE, Gonzalez-Farre B, Nicolae A, et al. MAPK and JAK-STAT pathways dysregulation in plasmablastic lymphoma. Haematologica. 2021;106(10):2682-2693. doi:10.3324/HAEMATOL.2020.271957
Witte HM, Künstner A, Hertel N, et al. Integrative genomic and transcriptomic analysis in plasmablastic lymphoma identifies disruption of key regulatory pathways. Blood Adv. 2022;6(2):637-651. doi:10.1182/BLOODADVANCES.2021005486
Hu Z, Pan Z, Chen W, et al. Primary effusion lymphoma: a Clinicopathological study of 70 cases. Cancers (Basel). 2021;13(4):1-14. doi:10.3390/CANCERS13040878
Shimada K, Hayakawa F, Kiyoi H. Biology and management of primary effusion lymphoma. Blood. 2018;132(18):1879-1888. doi:10.1182/BLOOD-2018-03-791426
Mullaney BP, Ng VL, Herndier BG, McGrath MS, Pallavicini MG. Comparative genomic analyses of primary effusion lymphoma. Arch Pathol Lab Med. 2000;124(6):824-826. doi:10.5858/2000-124-0824-CGAOPE
Chadburn A, Said J, Gratzinger D, et al. HHV8/KSHV-positive lymphoproliferative disorders and the Spectrum of Plasmablastic and plasma cell neoplasms: 2015 SH/EAHP workshop report-part 3. Am J Clin Pathol. 2017;147(2):171-187. doi:10.1093/AJCP/AQW218
Foster WR, Bischin A, Dorer R, Aboulafia DM. Human herpesvirus type 8-associated large B-cell lymphoma: a nonserous Extracavitary variant of primary effusion lymphoma in an HIV-infected man: a case report and review of the literature. Clin Lymphoma Myeloma Leuk. 2016;16(6):311-321. doi:10.1016/J.CLML.2016.03.013
Lap CJ, Nassereddine S, Dunleavy K. Novel biological insights and new developments in Management of Burkitt Lymphoma and High-Grade B-cell lymphoma. Curr Treat Options in Oncol. 2021;22(7):60. doi:10.1007/S11864-021-00857-W
Mbulaiteye SM, Anderson WF, Bhatia K, Rosenberg PS, Linet MS, Devesa SS. Trimodal age-specific incidence patterns for Burkitt lymphoma in the United States, 1973-2005. Int J Cancer. 2010;126(7):1732-1739. doi:10.1002/IJC.24934
Sukswai N, Lyapichev K, Khoury JD, Medeiros LJ. Diffuse large B-cell lymphoma variants: an update. Pathology. 2020;52(1):53-67. doi:10.1016/J.PATHOL.2019.08.013
Dávila Saldaña BJ, John T, Bonifant C, et al. High risk of relapsed disease in patients with NK/T-cell chronic active Epstein-Barr virus disease outside of Asia. Blood Adv. 2022;6(2):452-459. doi:10.1182/BLOODADVANCES.2021005291
Wei N, Wang Y, Wang J, Wu L, Wang Z. Characteristics of Epstein-Barr virus reactivation after allogeneic haematopoietic stem cell transplantation in patients with chronic active Epstein-Barr virus disease: favorable responses to rituximab. Bone Marrow Transplant. 2021;56(6):1449-1451. doi:10.1038/S41409-020-01193-7
Kimura H, Cohen JI. Chronic active Epstein-Barr virus disease. Front Immunol. 2017;8(DEC):22. doi:10.3389/FIMMU.2017.01867
Arai A. Advances in the study of chronic active Epstein-Barr virus infection: clinical features under the 2016 WHO classification and mechanisms of development. Front Pediatr. 2019;7:14. doi:10.3389/FPED.2019.00014
Chiba S, Sakata-Yanagimoto M. Advances in understanding of angioimmunoblastic T-cell lymphoma. Leukemia. 2020;34(10):2592-2606. doi:10.1038/S41375-020-0990-Y
Iqbal J, Wright G, Wang C, et al. Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma. Blood. 2014;123(19):2915-2923. doi:10.1182/BLOOD-2013-11-536359
Dunleavy K, Roschewski M, Wilson WH. Lymphomatoid granulomatosis and other Epstein-Barr virus associated lymphoproliferative processes. Curr Hematol Malig Rep. 2012;7(3):208. doi:10.1007/S11899-012-0132-3
Melani C, Jaffe ES, Wilson WH. Pathobiology and treatment of lymphomatoid granulomatosis, a rare EBV-driven disorder. Blood. 2020;135(16):1344-1352. doi:10.1182/BLOOD.2019000933
Song JY, Pittaluga S, Dunleavy K, et al. Lymphomatoid granulomatosis, a single institute experience: pathologic findings and clinical correlations. Am J Surg Pathol. 2015;39(2):141-156. doi:10.1097/PAS.0000000000000328
Ok CY, Li L, Young KH. EBV-driven B-cell lymphoproliferative disorders: from biology, classification and differential diagnosis to clinical management. Exp Mol Med. 2015;47(1):e132. doi:10.1038/EMM.2014.82
Oyama T, Yamamoto K, Asano N, et al. Age-related EBV-associated B-cell lymphoproliferative disorders constitute a distinct clinicopathologic group: a study of 96 patients. Clin Cancer Res. 2007;13(17):5124-5132. doi:10.1158/1078-0432.CCR-06-2823
Morales D, Beltran B, De Mendoza FH, et al. Epstein-Barr virus as a prognostic factor in de novo nodal diffuse large B-cell lymphoma. Leuk Lymphoma. 2010;51(1):66-72. doi:10.3109/10428190903308015
Ahn JS, Yang DH, Duk Choi Y, et al. Clinical outcome of elderly patients with Epstein-Barr virus positive diffuse large B-cell lymphoma treated with a combination of rituximab and CHOP chemotherapy. Am J Hematol. 2013;88(9):774-779. doi:10.1002/AJH.23507
Beltran BE, Quiñones P, Morales D, et al. Response and survival benefit with chemoimmunotherapy in Epstein-Barr virus-positive diffuse large B-cell lymphoma. Hematol Oncol. 2018;36(1):93-97. doi:10.1002/HON.2449
Sato A, Nakamura N, Kojima M, et al. Clinical outcome of Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly in the rituximab era. Cancer Sci. 2014;105(9):1170-1175. doi:10.1111/CAS.12467
Keane C, Tobin J, Gunawardana J, et al. The tumour microenvironment is immuno-tolerogenic and a principal determinant of patient outcome in EBV-positive diffuse large B-cell lymphoma. Eur J Haematol. 2019;103(3):200-207. doi:10.1111/EJH.13274
International Non-Hodgkin's Lymphoma Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993;329(14):987-994. doi:10.1056/NEJM199309303291402
Beltran BE, Castro D, Villela L, et al. A novel prognostic index for patients with EBV-DLBCL NOS: a study from the Grupo De Estudio Latinoamericano De Linfoproliferativos (GELL). Blood. 2021;138(Supplement 1):1436. doi:10.1182/BLOOD-2021-151389
Witte HM, Merz H, Biersack H, et al. Impact of treatment variability and clinicopathological characteristics on survival in patients with Epstein-Barr-virus positive diffuse large B cell lymphoma. Br J Haematol. 2020;189(2):257-268. doi:10.1111/BJH.16342
Kim SJ, Hyeon J, Cho I, Ko YH, Kim WS. Comparison of efficacy of Pembrolizumab between Epstein-Barr virus-positive and -negative relapsed or refractory non-Hodgkin lymphomas. Cancer Res Treat. 2019;51(2):611-622. doi:10.4143/CRT.2018.191
Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med. 1997;3(8):917-921. doi:10.1038/NM0897-917
Liu Z, Xu-Monette ZY, Cao X, et al. Prognostic and biological significance of survivin expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy. Mod Pathol. 2015;28(10):1297-1314. doi:10.1038/MODPATHOL.2015.94
Hong JY, Ryu KJ, Park C, et al. Clinical impact of serum survivin positivity and tissue expression of EBV-encoded RNA in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. Oncotarget. 2017;8(8):13782-13791. doi:10.18632/ONCOTARGET.14636
Barros MHM, Hauck F, Dreyer JH, Kempkes B, Niedobitek G. Macrophage polarisation: an immunohistochemical approach for identifying M1 and M2 macrophages. PLoS ONE. 2013;8(11):e80908. doi:10.1371/JOURNAL.PONE.0080908
Gu YY, Luo B, Li CY, et al. Expression and clinical significance of neuropilin-1 in Epstein-Barr virus-associated lymphomas. Cancer Biomark. 2019;25(3):259-273. doi:10.3233/CBM-192437
Pfreundschuh M, Kuhnt E, Trümper L, et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera international trial (MInT) group. Lancet Oncol. 2011;12(11):1013-1022. doi:10.1016/S1470-2045(11)70235-2
Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006;24(19):3121-3127. doi:10.1200/JCO.2005.05.1003
Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood. 2010;116(12):2040-2045. doi:10.1182/BLOOD-2010-03-276246
Svoboda J, Bair SM, Landsburg DJ, et al. Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas. Haematologica. 2021;106(6):1705-1713. doi:10.3324/HAEMATOL.2019.238675
Tilly H, Morschhauser F, Sehn LH, et al. Polatuzumab Vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med. 2022;386(4):351-363. doi:10.1056/NEJMOA2115304
Van Imhoff GW, McMillan A, Matasar MJ, et al. Ofatumumab versus rituximab salvage Chemoimmunotherapy in relapsed or refractory diffuse large B-cell lymphoma: the ORCHARRD study. J Clin Oncol. 2017;35(5):544-551. doi:10.1200/JCO.2016.69.0198
Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28(27):4184-4190. doi:10.1200/JCO.2010.28.1618
Crump M, Kuruvilla J, Couban S, et al. Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12. J Clin Oncol. 2014;32(31):3490-3496. doi:10.1200/JCO.2013.53.9593
Thieblemont C, Briere J, Mounier N, et al. The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study. J Clin Oncol. 2011;29(31):4079-4087. doi:10.1200/JCO.2011.35.4423
Fenske TS, Ahn KW, Graff TM, et al. Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation. Br J Haematol. 2016;174(2):235-248. doi:10.1111/BJH.14046
Bento L, Gutiérrez A, Novelli S, et al. Allogeneic stem cell transplantation as a curative option in relapse/refractory diffuse large B cell lymphoma: Spanish multicenter GETH/GELTAMO study. Bone Marrow Transplant. 2021;56(8):1919-1928. doi:10.1038/S41409-021-01264-3
Kanate AS, Majhail NS, Savani BN, et al. Indications for hematopoietic cell transplantation and immune effector cell therapy: guidelines from the American Society for Transplantation and Cellular Therapy. Biol Blood Marrow Transplant. 2020;26(7):1247-1256. doi:10.1016/J.BBMT.2020.03.002
Hamadani M, Gopal AK, Pasquini M, et al. Allogeneic transplant and CAR-T therapy after autologous transplant failure in DLBCL: a noncomparative cohort analysis. Blood Adv. 2022;6(2):486-494. doi:10.1182/BLOODADVANCES.2021005788
Dreger P, Fenske TS, Montoto S, Pasquini MC, Sureda A, Hamadani M. Cellular immunotherapy for refractory diffuse large B cell lymphoma in the chimeric antigen receptor-engineered T cell era: still a role for allogeneic transplantation? Biol Blood Marrow Transplant. 2020;26(4):e77-e85. doi:10.1016/J.BBMT.2019.12.771
Locke FL, Miklos DB, Jacobson CA, et al. Axicabtagene Ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med. 2022;386(7):640-654. doi:10.1056/NEJMOA2116133
Ghosh SK, Perrine SP, Faller DV. Advances in virus-directed therapeutics against Epstein-Barr virus-associated malignancies. Adv Virol. 2012;2012:1-11. doi:10.1155/2012/509296
Liebowitz D. Epstein-Barr virus and a cellular signaling pathway in lymphomas from immunosuppressed patients. N Engl J Med. 1998;338(20):1413-1421. doi:10.1056/NEJM199805143382003
Perrine SP, Hermine O, Small T, et al. A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies. Blood. 2007;109(6):2571-2578. doi:10.1182/BLOOD-2006-01-024703
Haverkos BM, Alpdogan O, Baiocchi R, et al. Nanatinostat (Nstat) and Valganciclovir (VGCV) in relapsed/refractory (R/R) Epstein-Barr virus-positive (EBV +) lymphomas: final results from the phase 1b/2 VT3996-201 study. Blood. 2021;138(Supplement 1):623. doi:10.1182/BLOOD-2021-152603
Ghosh SK, Perrine SP, Williams RM, Faller DV. Histone deacetylase inhibitors are potent inducers of gene expression in latent EBV and sensitize lymphoma cells to nucleoside antiviral agents. Blood. 2012;119(4):1008-1017. doi:10.1182/BLOOD-2011-06-362434
Caldwell RG, Wilson JB, Anderson SJ, Longnecker R. Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals. Immunity. 1998;9(3):405-411. doi:10.1016/S1074-7613(00)80623-8
Craxton A, Jiang A, Kurosaki T, Clark EA. Syk and Bruton's tyrosine kinase are required for B cell antigen receptor-mediated activation of the kinase Akt. J Biol Chem. 1999;274(43):30644-30650. doi:10.1074/JBC.274.43.30644
Tempera I, Lieberman PM. Epigenetic regulation of EBV persistence and oncogenesis. Semin Cancer Biol. 2014;26:22-29. doi:10.1016/J.SEMCANCER.2014.01.003
Yoon SE, Kim SJ, Yoon DH, et al. A phase II study of ibrutinib in combination with rituximab-cyclophosphamide-doxorubicin hydrochloride-vincristine sulfate-prednisone therapy in Epstein-Barr virus-positive, diffuse large B cell lymphoma (54179060LYM2003: IVORY study): results of the final analysis. Ann Hematol. 2020;99(6):1283-1291. doi:10.1007/S00277-020-04005-6
Kato H, Karube K, Yamamoto K, et al. Gene expression profiling of Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly reveals alterations of characteristic oncogenetic pathways. Cancer Sci. 2014;105(5):537-544. doi:10.1111/CAS.12389
Lam LT, Wright G, Davis RE, et al. Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma. Blood. 2008;111(7):3701-3713. doi:10.1182/BLOOD-2007-09-111948
Scuto A, Kujawski M, Kowolik C, et al. STAT3 inhibition is a therapeutic strategy for ABC-like diffuse large B-cell lymphoma. Cancer Res. 2011;71(9):3182-3188. doi:10.1158/0008-5472.CAN-10-2380
Zou P, Kawada J, Pesnicak L, Cohen JI. Bortezomib induces apoptosis of Epstein-Barr virus (EBV)-transformed B cells and prolongs survival of mice inoculated with EBV-transformed B cells. J Virol. 2007;81(18):10029-10036. doi:10.1128/JVI.02241-06
Offner F, Samoilova O, Osmanov E, et al. Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL. Blood. 2015;126(16):1893-1901. doi:10.1182/BLOOD-2015-03-632430
Ruan J, Martin P, Furman RR, et al. Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. J Clin Oncol. 2011;29(6):690-697. doi:10.1200/JCO.2010.31.1142
Zhang LH, Kosek J, Wang M, Heise C, Schafer PH, Chopra R. Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression. Br J Haematol. 2013;160(4):487-502. doi:10.1111/BJH.12172
Hernandez-Ilizaliturri FJ, Deeb G, Zinzani PL, et al. Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype. Cancer. 2011;117(22):5058-5066. doi:10.1002/CNCR.26135
Thieblemont C, Tilly H, Da Silva MG, et al. Lenalidomide maintenance compared with placebo in responding elderly patients with diffuse large B-cell lymphoma treated with first-line rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2017;35(22):2473-2481. doi:10.1200/JCO.2017.72.6984
Nowakowski GS, LaPlant B, Macon WR, et al. Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-cell lymphoma: a phase II study. J Clin Oncol. 2015;33(3):251-257. doi:10.1200/JCO.2014.55.5714
Kloo B, Nagel D, Pfeifer M, et al. Critical role of PI3K signaling for NF-κB-dependent survival in a subset of activated B-cell-like diffuse large B-cell lymphoma cells. Proc Natl Acad Sci U S A. 2011;108(1):272-277. doi:10.1073/PNAS.1008969108/-/DCSUPPLEMENTAL/PNAS.201008969SI.PDF
Liu JY, Kenney T, Butterworth L, et al. Abstract 2673: Idelalisib has activity at clinically achievable drug concentrations in a subset of ABC and GCB diffuse large B-cell lymphoma and transformed follicular lymphoma cell lines. Cancer Res. 2015;75(15 Supplement):2673. doi:10.1158/1538-7445.AM2015-2673
Leen AM, Rooney CM, Foster AE. Improving T cell therapy for cancer. Annu Rev Immunol. 2007;25:243-265. doi:10.1146/ANNUREV.IMMUNOL.25.022106.141527
Blattman JN, Greenberg PD. Cancer immunotherapy: a treatment for the masses. Science. 2004;305(5681):200-205. doi:10.1126/SCIENCE.1100369
Papadopoulos EB, Ladanyi M, Emanuel D, et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med. 1994;330(17):1185-1191. doi:10.1056/NEJM199404283301703
Rooney CM, Ng CYC, Loftin S, et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet (London, England). 1995;345(8941):9-13. doi:10.1016/S0140-6736(95)91150-2
Savoldo B, Goss JA, Hammer MM, et al. Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs). Blood. 2006;108(9):2942-2949. doi:10.1182/BLOOD-2006-05-021782
Heslop HE, Slobod KS, Pule MA, et al. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood. 2010;115(5):925-935. doi:10.1182/BLOOD-2009-08-239186
Feuchtinger T, Matthes-Martin S, Richard C, et al. Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation. Br J Haematol. 2006;134(1):64-76. doi:10.1111/J.1365-2141.2006.06108.X
Cobbold M, Khan N, Pourgheysari B, et al. Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J Exp Med. 2005;202(3):379-386. doi:10.1084/JEM.20040613
Gerdemann U, Christin AS, Vera JF, et al. Nucleofection of DCs to generate multivirus-specific T cells for prevention or treatment of viral infections in the immunocompromised host. Mol Ther J Am Soc Gene Ther. 2009;17(9):1616-1625. doi:10.1038/MT.2009.140
Icheva V, Kayser S, Wolff D, et al. Adoptive transfer of epstein-barr virus (EBV) nuclear antigen 1-specific t cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem-cell transplantation. J Clin Oncol. 2013;31(1):39-48. doi:10.1200/JCO.2011.39.8495
Bollard CM, Gottschalk S, Torrano V, et al. Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins. J Clin Oncol. 2014;32(8):798-808. doi:10.1200/JCO.2013.51.5304
Prockop S, Doubrovina E, Suser S, et al. Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation. J Clin Invest. 2020;130(2):733-747. doi:10.1172/JCI121127
Torno L, Dahlberg A, Ghobadi A, et al. Clinical experience of Tabelecleucel in patients with life-threatening complications of Epstein-Barr virus viremia. Blood. 2020;136(Supplement 1):7-8. doi:10.1182/BLOOD-2020-136052
Kurlander LS, Srinivasan A, Ghobadi A, et al. Efficacy and safety of tabelecleucel in patients with EpsteinBarr virus-associated leiomyosarcomas (EBV+ LMS). Ann Oncol. 2018;29:x12. doi:10.1093/ANNONC/MDY485.003
Prockop S, Mahadeo KM, Beitinjaneh A, et al. Multicenter, open-label, phase 3 study of Tabelecleucel for solid organ or allogeneic hematopoietic cell transplant recipients with Epstein-Barr virus-driven post transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE). Blood. 2021;138(Supplement 1):301. doi:10.1182/BLOOD-2021-147274
Dalton T, Doubrovina E, Pankov D, et al. Epigenetic reprogramming sensitizes immunologically silent EBV+ lymphomas to virus-directed immunotherapy. Blood. 2020;135(21):1870-1881. doi:10.1182/BLOOD.2019004126
Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8(8):793-800. doi:10.1038/NM730
Hu L-Y, Xu X-L, Rao H-L, et al. Expression and clinical value of programmed cell death-ligand 1 (PD-L1) in diffuse large B cell lymphoma: a retrospective study. Chin J Cancer. 2017;36(1):94. doi:10.1186/S40880-017-0262-Z
Kiyasu J, Miyoshi H, Hirata A, et al. Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma. Blood. 2015;126(19):2193-2201. doi:10.1182/BLOOD-2015-02-629600
Chen BJ, Chapuy B, Ouyang J, et al. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin Cancer Res. 2013;19(13):3462-3473. doi:10.1158/1078-0432.CCR-13-0855
Rossille D, Gressier M, Damotte D, et al. High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-cell lymphoma: results from a French multicenter clinical trial. Leukemia. 2014;28(12):2367-2375. doi:10.1038/LEU.2014.137
Quan L, Chen X, Liu A, et al. PD-1 blockade can restore functions of T-cells in Epstein-Barr virus-positive diffuse large B-cell lymphoma in vitro. PLoS ONE. 2015;10(9):e0136476. doi:10.1371/JOURNAL.PONE.0136476
Yilmaz E, Lakhotia R, Pittaluga S, et al. Phase 2 study of Nivolumab in Epstein-Barr virus (EBV)-positive lymphoproliferative disorders and EBV-positive non-Hodgkin lymphomas. Blood. 2021;138(Supplement 1):4504. doi:10.1182/BLOOD-2021-151824
Chavez JC, Bachmeier C, Kharfan-Dabaja MA. CAR T-cell therapy for B-cell lymphomas: clinical trial results ofavailable products. Ther Adv Hematol. 2019;10:204062071984158. doi:10.1177/2040620719841581
Sheykhhasan M, Manoochehri H, Dama P. Use of CAR T-cell for acute lymphoblastic leukemia (ALL) treatment: a review study. Cancer Gene Ther. Published online January, 5 2022. doi:10.1038/s41417-021-00418-1
Tang X, Zhou Y, Li W, et al. T cells expressing a LMP1-specific chimeric antigen receptor mediate antitumor effects against LMP1-positive nasopharyngeal carcinoma cells in vitro and in vivo. J Biomed Res. 2014;28(6):468-475. doi:10.7555/JBR.28.20140066
Slabik C, Kalbarczyk M, Danisch S, et al. CAR-T cells targeting Epstein-Barr virus gp350 validated in a humanized mouse model of EBV infection and lymphoproliferative disease. Mol Ther - Oncolytics. 2020;18:504-524. doi:10.1016/J.OMTO.2020.08.005
Il CH, Kim UH, Shin AR, et al. A novel Epstein-Barr virus-latent membrane protein-1-specific T-cell receptor for TCR gene therapy. Br J Cancer. 2018;118(4):534-545. doi:10.1038/bjc.2017.475
Yu M, Zhang Q, Xu S, Yin T, Li F. Successful treatment of refractory retroperitoneal Epstein-Barr virus-positive diffuse large B-cell lymphoma with secondary hemophagocytic syndrome by sequential combination regimen of PD-1 blockade and chimeric antigen receptor T cells: a case report. Anti-Cancer Drugs. 2022;33(1):e769-e775. doi:10.1097/CAD.0000000000001187
Strunz PP, Schmalzing M, Heidemeier A, Rasche L, Einsele H, Kortüm KM. Response to daratumumab in rituximab-resistant EBV-associated PTLD following allogenic stem cell transplantation from an EBV seronegative donor. Leuk Lymphoma. 2019;60(14):3573-3576. doi:10.1080/10428194.2019.1636981
Mika T, Strate K, Ladigan S, et al. Refractory Epstein-Barr virus (EBV)-related post-transplant lymphoproliferative disease: cure by combined Brentuximab Vedotin and allogeneic EBV-specific T-lymphocytes. Front Med. 2019;6:295. doi:10.3389/FMED.2019.00295
Kim M, Lee JO, Koh J, et al. A phase II study of brentuximab vedotin in patients with relapsed or refractory Epstein-Barr virus-positive and CD30-positive lymphomas. Haematologica. 2021;106(8):2277-2280. doi:10.3324/HAEMATOL.2021.278301
Taylor GS, Jia H, Harrington K, et al. A recombinant modified vaccinia Ankara vaccine encoding Epstein-Barr virus (EBV) target antigens: a phase I trial in UKpatients with EBV-positive cancer. Clin Cancer Res. 2014;20(19):5009-5022. doi:10.1158/1078-0432.CCR-14-1122-T
Cui X, Snapper CM. Epstein Barr virus: development of vaccines and immune cell therapy for EBV-associated diseases. Front Immunol. 2021;12:734471. doi:10.3389/FIMMU.2021.734471